Ovarian cancer is one of the most lethal gynecologic cancers.The standard therapy for ovarian cancer has been the same for the past two decades,a combination treatment of platinum with paclitaxel.Recently,the FDA appr...Ovarian cancer is one of the most lethal gynecologic cancers.The standard therapy for ovarian cancer has been the same for the past two decades,a combination treatment of platinum with paclitaxel.Recently,the FDA approved three new therapeutic drugs,two poly(ADP-ribose)polymerase inhibitors(olaparib and niraparib)and one vascular endothelial growth factor inhibitor(bevacizumab)as maintenance therapies for ovarian cancer.In this review,we summarize the resistance mechanisms for conventional platinum-based chemotherapy and for the newly FDA-approved drugs.展开更多
文摘Ovarian cancer is one of the most lethal gynecologic cancers.The standard therapy for ovarian cancer has been the same for the past two decades,a combination treatment of platinum with paclitaxel.Recently,the FDA approved three new therapeutic drugs,two poly(ADP-ribose)polymerase inhibitors(olaparib and niraparib)and one vascular endothelial growth factor inhibitor(bevacizumab)as maintenance therapies for ovarian cancer.In this review,we summarize the resistance mechanisms for conventional platinum-based chemotherapy and for the newly FDA-approved drugs.
